Adjuvant treatment of colorectal cancer - PubMed (original) (raw)

. 2008 Jul;2(4 Suppl):S42-6.

Affiliations

• PMID: 19343149
• PMCID: PMC2661542

Adjuvant treatment of colorectal cancer

Alfredo Carrato. Gastrointest Cancer Res. 2008 Jul.

Abstract

Many patients with stage III colon cancer, and selected patients with stage II disease, will obtain significant benefit from adjuvant chemotherapy. Combination regimens that include a fluoropyrimidine plus oxaliplatin are the current standard of care, based on findings from the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) and the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 trials. Ongoing randomized trials are evaluating oral fluoropyrimidines combined with oxaliplatin and the addition of targeted therapies to oxaliplatin-based regimens for use in colon cancer adjuvant treatment. Adjuvant treatment approaches for patients with rectal cancer (stage II and III) now include preoperative chemoradiotherapy, based on a phase III comparison of preoperative vs. postoperative chemoradiotherapy conducted in Germany. Ongoing trials are evaluating new cytotoxic and target-oriented agents used in both the neoadjuvant and adjuvant settings in these patients. Improved surgical and radiotherapy techniques may also contribute to superior patient outcomes. Additional research is needed to identify patient subgroups at risk for recurrence, predictive factors for treatment response, and better treatment strategies for patients with colon and rectal cancer.

PubMed Disclaimer

Similar articles

• Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
  Hong YS, Nam BH, Kim KP, Kim JE, Park SJ, Park YS, Park JO, Kim SY, Kim TY, Kim JH, Ahn JB, Lim SB, Yu CS, Kim JC, Yun SH, Kim JH, Park JH, Park HC, Jung KH, Kim TW. Hong YS, et al. Lancet Oncol. 2014 Oct;15(11):1245-53. doi: 10.1016/S1470-2045(14)70377-8. Epub 2014 Sep 4. Lancet Oncol. 2014. PMID: 25201358 Clinical Trial.
• New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease.
  Benson AB 3rd. Benson AB 3rd. Clin Cancer Res. 2007 Nov 15;13(22 Pt 2):6913s-20s. doi: 10.1158/1078-0432.CCR-07-1188. Clin Cancer Res. 2007. PMID: 18006800 Review.
• A systematic overview of chemotherapy effects in colorectal cancer.
  Ragnhammar P, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. Ragnhammar P, et al. Acta Oncol. 2001;40(2-3):282-308. doi: 10.1080/02841860151116367. Acta Oncol. 2001. PMID: 11441937 Review.
• National Surgical Adjuvant Breast and Bowel Project trials in colon cancer.
  Wolmark N, Colangelo L, Wieand S. Wolmark N, et al. Semin Oncol. 2001 Feb;28(1 Suppl 1):9-13. doi: 10.1016/s0093-7754(01)90245-3. Semin Oncol. 2001. PMID: 11273592
• Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
  Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Schmoll HJ, et al. Lancet Oncol. 2014 Dec;15(13):1481-1492. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12. Lancet Oncol. 2014. PMID: 25456367 Free PMC article. Clinical Trial.

Cited by

• Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.
  Gmeiner WH. Gmeiner WH. Cancers (Basel). 2020 Jun 21;12(6):1641. doi: 10.3390/cancers12061641. Cancers (Basel). 2020. PMID: 32575843 Free PMC article. Review.
• Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer.
  Xiaoyuan C, Longbang C, Jinghua W, Xiaoxiang G, Huaicheng G, Qun Z, Haizhu S. Xiaoyuan C, et al. Ir J Med Sci. 2010 Sep;179(3):327-35. doi: 10.1007/s11845-009-0448-8. Epub 2009 Nov 17. Ir J Med Sci. 2010. PMID: 19921309
• The role of mouse models in colorectal cancer research-The need and the importance of the orthotopic models.
  Oliveira RC, Abrantes AM, Tralhão JG, Botelho MF. Oliveira RC, et al. Animal Model Exp Med. 2020 Mar 11;3(1):1-8. doi: 10.1002/ame2.12102. eCollection 2020 Mar. Animal Model Exp Med. 2020. PMID: 32318654 Free PMC article. Review.
• Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells.
  Rauch A, Carlstedt A, Emmerich C, Mustafa AM, Göder A, Knauer SK, Linnebacher M, Heinzel T, Krämer OH. Rauch A, et al. Oncotarget. 2018 Jun 12;9(45):27835-27850. doi: 10.18632/oncotarget.25600. eCollection 2018 Jun 12. Oncotarget. 2018. PMID: 29963241 Free PMC article.
• Patient perspectives on treatment decision-making under clinical uncertainty: chemotherapy treatment decisions among stage II colon cancer patients.
  Brotzman LE, Crookes DM, Austin JD, Neugut AI, Shelton RC. Brotzman LE, et al. Transl Behav Med. 2021 Oct 23;11(10):1905-1914. doi: 10.1093/tbm/ibab040. Transl Behav Med. 2021. PMID: 34042154 Free PMC article.

References

1. 1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. - PubMed
2. 1. Le Voyer TE, Sigurdson ER, Hanion AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of Intergroup trial INT-0089. J Clin Oncol. 2003;21:2912–2919. - PubMed
3. 1. Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451:147–152. - PMC - PubMed
4. 1. Wolmark N, Fisher B, Rockette H, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst. 1988;80:30–36. - PubMed
5. 1. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–358. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central